This study introduces JS207, a novel BsAb targeting PD-1 and VEGFA, engineered to overcome resistance mechanisms in cancer therapy by concurrently inhibiting immunosuppressive and angiogenic pathways. The gene discussed is VEGFA; the disease is cancer.